^
    3d
    Fecal Molecular Susceptibility-guided Hp Rescue Therapy (clinicaltrials.gov)
    P4, N=290, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • HEOR
    |
    minocycline
    3d
    Fecal Molecular Susceptibility-guided Hp First-line Therapy (clinicaltrials.gov)
    P4, N=544, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • HEOR
    |
    minocycline
    3d
    Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis (clinicaltrials.gov)
    P2, N=172, Recruiting, National University of Malaysia
    New P2 trial
    5d
    Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, University of California, Irvine | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    7d
    Microglia alter autonomic nuclei neuronal activation after peripheral cytokine challenge. (PubMed, Am J Physiol Cell Physiol)
    When animals were challenged with TNFα after receiving minocycline, fewer c-Fos-positive cells were induced in the DVC and selectively in the rostral VLM. These findings highlight the spatial selectivity of cells in the brainstem to increased peripheral pro-inflammatory signaling, as well as the impact of resident microglia on autonomic circuitry responses.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    |
    minocycline
    10d
    COBRA: Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis (clinicaltrials.gov)
    P=N/A, N=440, Active, not recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Active, not recruiting
    Enrollment closed
    11d
    Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Medstar Health Research Institute
    New trial
    11d
    Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation. (PubMed, JCI Insight)
    Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRAS-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in bAVM patients.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    KRAS mutation • KRAS G12
    |
    minocycline
    12d
    Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=65, Completed, First Affiliated Hospital of Zhejiang University | Recruiting --> Completed | N=30 --> 65 | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    cytarabine • cladribine • Synribo (omacetaxine mepesuccinate)
    12d
    Artemether as a modulator of EMT in colorectal cancer: enhancing radiosensitivity and reversing chemo-radiation resistance. (PubMed, BMC Gastroenterol)
    These findings provide both mechanistic insights and experimental validation for the potential application of ARE as a radiosensitizer in colorectal cancer radiotherapy.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
    13d
    Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Daewon Pharmaceutical Co., Ltd.
    New P1 trial
    15d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)